Trial Profile

A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms IMpower151
Sponsors Roche

19 Jul 2024 Status changed from active, no longer recruiting to completed.
10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
12 Sep 2023 Primary endpoint (Progression Free Survival (PFS) in the intent to treat (ITT) population, as determined by the investigator) has not been met according to Results presented at the 24th World Conference on Lung Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com